Throughout Community Impact Week, Aprio volunteers completed projects at nonprofit organizations in Atlanta, Birmingham, Charlotte, Rockville, and more. With causes ranging from food scarcity to housing support, organizations supported included Bobby Dodd Institute in Atlanta, Community Food Bank of Central Alabama in Birmingham, Red Hook Farms in New York, Families Forward in Charlotte, and Duyan Ni Maria Children’s Home in the Philippines.
“As a non-profit organization, Chattahoochee Nature Center relies on corporate partners like Aprio to support our mission to connect people with nature,” said a spokesperson from Chattahoochee Nature Center. “We are grateful for the Aprio volunteers who worked to restore a critical trail so our 45,000 visiting school children can explore and interpret a new section of woodlands in the Chattahoochee River ecosystem. Thank you for your shared commitment to the environment and education. Together, we can preserve and protect the environment for future generations.”
About Aprio: Aprio is a premier, full-service business advisory and accounting firm that advises clients on achieving what’s next. Aprio professionals work as integrated teams across advisory, audit, tax, outsourcing, talent solutions and private client services, bringing the best thinking and personal commitment to each client. Across practices, Aprio brings together proven expertise, deep understanding and strategic foresight for industries including Manufacturing and Distribution; Non-Profit and Education; Professional Services; Real Estate; Construction; Retail, Franchise and Hospitality; Government Contracting, and Technology and Blockchain. Aprio has grown to over 2,000 team members. To serve clients wherever life or business may take them, Aprio’s teams speak more than 60+ languages and work with clients in over 50 countries. For more, visit http://www.aprio.com/.
Brent also gives thanks to Rutemiller’s Army, the group of friends, family members, colleagues and Olympians from the swimming community, who came together to support Brent from diagnosis to partial remission.
“Over the past two years, all my treatments failed to conquer the Multiple Myeloma cancer circulating in my blood. I went through two stem cell transplants, chemotherapy, multiple drug treatments, and cataract, brain, and heart surgery. Along the way, I lost my eyesight, hearing, smell, taste, and feeling in my face, chin, right leg, and toes. But I never lost hope because of the support from the swimming community and Rutemiller’s Army. Now is the time to give back,” said Brent.
Today, Brent has responded well to treatment, surpassing even his doctor’s expectations. He has miraculously recovered and has regained much of his health so that he can swim once again. To mark this occasion, Brent will be swimming in two Arizona pools on November 24-27 and he is encouraging anyone who loves swimming to dive in and join him. He will be joined virtually at other locations by his faithful Rutemiller’s Army, and special guests from his swimming career, including Olympic swimmers Rowdy Gaines, Debbie Meyer, Nathan Adrian, Aaron Peirsol, Elizabeth Beisel, Matt Grevers, Amanda Beard, Roland Schoeman and Darian Townsend. Those who live outside the Arizona-area and want to join in and swim and support Rutemiller’s Army, can swim in their local pool and donate to Rutemiller’s Army.
Brent’s journey to remission is full of many ups and downs, and he has maintained a positive, yet realistic outlook. His story is documented in a self-produced video on swimacrossamerica.org/rutemillersarmy.
“There is no cure for multiple myeloma – there are only treatments,” said Brent. “I am calling on Rutemiller’s Army to swim for a cure.”
Brent is no stranger to the strength of the swimming community. In 1985, he began his association with Swimming World Magazine and he went on to serve as marketing director, publisher, CEO and owner of the magazine. After a 37-year tenure with the publication, he became CEO of the International Swimming Hall of Fame (ISHOF), re-establishing its home in Fort Lauderdale, Florida, and merging the magazine and its multimedia platforms with the Hall. His leadership was integral to the ongoing construction of the Hall’s new facilities, which include the first high-diving tower of its kind in the world. He retired from his magazine and Hall of Fame positions in 2022 after his cancer diagnosis.
In June 2021, Brent discovered what he believed to be a kidney stone causing intense back pain. It was instead a rare bone marrow cancer called plasma cell leukemia or multiple myeloma. He started chemotherapy almost immediately with MD Anderson before being transferred to Mayo Clinic in Phoenix, Arizona.
Then in January 2022, he experienced the first setback by suffering a skin reaction to one of his major medications. Doctors took him off the drug and began discussions for a bone marrow transplant. They were hopeful that a stem cell transplant would help conquer the cancer in his blood. With the cancer growing at an exponential rate, they infused Brent with five million stem cells in March, 2022. Within a month his cancer was under control and in early remission.
However, seven months later in September 2022, his cancer returned. He received radiation for cancer in his jaw and began the process of receiving Chimeric antigen receptor (CAR) T-cell therapy in the form of another bone marrow transplant. CAR T-cell therapy is a way to get immune cells called T cells to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer cells.
While waiting for the new, modified T cells to be transplanted, his cancer was intensifying. He received the CAR-T transplant in October and was briefly released from the hospital, though his marrow was not responding to the treatment. The following month while back in the hospital, he dealt with multiple setbacks including high fevers, poor clotting of wounds, and difficulty walking independently.
Ten days before Christmas, his marrow was still not responding. His wife suggested to his doctors to give Brent a stem cell boost with the five million of his stem cells that were still banked in cold storage. After the boost of three million stem cells, his initial tests showed no signs of cancer and he was released on December 28 – the day of his 37th wedding anniversary.
“I couldn’t wait to get home, hold my grandsons, get back in shape, and dive into the pool as soon as I felt strong enough,” said Brent.
In February 2023, Brent received test results from his doctors showing signs that the cancer was undetectable.
“They said I had the cleanest bone marrow they’d ever seen!” shared Brent. “We still needed to wait and let the cells do their job but that was fantastic news.”
Then in March, Brent fought another setback as he received the news that his cancer had returned again, and this time, in the form of a brain tumor. Doctors acted quickly and removed the tumor, leaving a large U-shaped scar on the back of his head.
He then learned that cancer had attacked his heart and a new brain tumor formed after the surgery. Brent received radiation treatments for the brain tumor and a pacemaker in his heart to combat the new diagnoses.
After treatment, Brent was feeling well enough to resume hiking and work on regaining his strength, even though the cancer was still growing in his blood.
“Then everything changed. In late 2022, the FDA had granted emergency approval for a new drug called Teclistamab for the treatment of adult patients with relapsed or refractory multiple myeloma,” said Brent. “I was lucky to have my doctors know this and I underwent treatment in May 2023. It was my last hope.”
After a 15-day treatment plan was implemented, Brent was feeling hopeful and healthy. His tests revealed that cancer levels in his blood were below normal and his brain tumor resolved. Brent was optimistic and slowly healing. In July 2023, Brent was in a state of “Very Good Partial Remission” and remains in that state today.
“Before that emergency FDA approval, we didn’t know what our next steps were. And to be honest, we still don’t know what will happen from here. But we’re hopeful and grateful, and I want Rutemiller’s Army to be my legacy and continue to fight towards a cure.”
Funds raised by Brent and Rutemiller’s Army will fund a cancer research project guided by the Swim Across America Research and Grants Committee.
Swim Across America was founded in 1987 with its first open water event in Long Island Sound. Since that time, the nonprofit organization has raised more than $100 million to fight cancer. In its 36 years of “making waves to fight cancer,” more than 100,000 swimmers and 150 Olympians have swum the circumference of the earth three times, uniting a movement to fight cancer that has created a groundswell of support spanning all generations. Today, more than 24 communities hold open water swims and charity pool swims each year, from Nantucket to under the Golden Gate Bridge, which support innovative cancer research, detection and patient programs.
Swim Across America’s funding of clinical trials for patients helped contribute to four FDA approved life-saving immunotherapy cancer treatments: Yervoy, Opdivo, Tecentriq and Keytruda. In June of last year, a clinical trial at Memorial Sloan Kettering was published in The New England Journal of Medicine that showed a 100 percent success rate in treating patients in a phase 2 clinical trial for advanced rectal cancer with dostarlimab, an immunotherapy treatment produced by GlaxoSmithKline. The clinical trial at Memorial Sloan Kettering was funded by early-stage grant funding from Swim Across America. More than 60 scientific grants are funded each year and there are now ten dedicated Swim Across America Labs at major institutions including: Children’s Healthcare of Atlanta, John Hopkins Medicine Baltimore, Rush University Medical Center Chicago, Baylor Scott & White Charles A. Sammons Cancer Center in Dallas, Memorial Sloan Kettering Cancer Center New York, Infusion Center at Nantucket Cottage Hospital, UCSF Benioff Children’s Hospital Oakland and San Francisco, the Seattle Cancer Care Alliance, The Swim Across America Pediatric Research Lab at Columbia University Medical Center New York, and at Meyer Cancer Center at Weill Cornell Medicine.
Swim Across America, Inc. (SAA) is dedicated to raising money and awareness for cancer research, prevention and treatment through swimming-related events. With the help of hundreds of volunteers nationwide and past and current Olympians, Swim Across America is helping find a cure for cancer through athleticism, community outreach and direct service. To learn more visitswimacrossamerica.org or follow on Facebook @SwimAcrossAmerica or on Instagram or Twitter @SAASwim.
Dr. Cunniffe, the lead author of the study, emphasized the importance of their findings, stating, “This study provides an update on state-of-the-art air cleaning technology to equip doctors to advise their patients effectively. HEPA filters were identified as the most efficient in removing airborne particles, including allergens and fine particulate matter. Furthermore, our research highlighted the remarkable effectiveness of activated carbon filters in eliminating volatile organic compounds (VOCs) and odors, while UV-based technology was found to be a valuable addition to filtered HVAC systems.”
The study’s recognition by ACAAI as part of their press kit underscores its significance in the field of allergology, asthma, and immunology. The iAIR Institute is proud to have its work highlighted at this prestigious event, emphasizing the Institute’s commitment to advancing and disseminating research, improving public policy and promoting the importance of healthier indoor environments for all.
The iAIR Institute’s research garnered significant interest and acclaim at the ACAAI Annual Scientific Meeting 2023. Attendees expressed enthusiasm for the study’s potential to enhance the medical community’s understanding of IAQ and provide valuable guidance for their patients.
Dr. John McKeon, CEO and Principal of the iAIR Institute, commented, “Our participation in the ACAAI Annual Scientific Meeting reaffirms our dedication to improving indoor air quality and supporting the healthcare community in their efforts to provide expert advice to patients. We encourage healthcare professionals to consider third-party tested air cleaning devices that are performance validated and, ideally, certified to relevant standards.”
The field of air cleaning technology is experiencing huge growth and evolving rapidly with research developments. Approaches such as electrostatic precipitation, photocatalytic oxidation and plasma-based air cleaning all demonstrate huge potential and are likely to positively impact IAQ across both residential and shared buildings in the future. The iAIR Institute looks forward to continued collaboration with fellow experts and researchers in the field of indoor air quality and remains dedicated to improving IAQ for the benefit of public health.
For more information about the study and the iAIR Institute’s contributions to IAQ research, please visit https://iair.institute.
About iAIR Institute
The iAIR Institute is a leading institution committed to advancing knowledge in the field of indoor air quality (IAQ). Through strategic partnerships and ground-breaking research initiatives, the Institute addresses crucial aspects such as consumer practices, labelling, product development, and the design of the built environment. Advocating for policy changes and empowering innovators with technical solutions, the iAIR Institute strives to enhance indoor air quality on a global scale.
The HITRUST risk-based, two-year certified status, initially awarded to the organization in September of 2022, confirmed Chapters Health’s hospice platforms met key regulations and industry-defined requirements and appropriately manage risk. The achievement elevated Chapters Health into exclusive group of organizations worldwide that have earned this certification. By including federal and state regulations, standards and frameworks, and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protections challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.
“The HITRUST Assurance Program is rigorous and reliable because of the comprehensiveness of control requirements, depth of review, and consistency of oversight” said Bimal Sheth, executive vice president, standards development & assurance operations, HITRUST. “HITRUST Risk-based, 2-year (r2) Certification demonstrates Chapters Health System is taking the most proactive approach to cybersecurity, data protection, and risk management.”
“HITRUST awarding the certification to Chapters Health for another year is the result of the collaboration and hard work from many teams in this organization,” said Mike Parkin, director, IT security CISO, Chapters Health System. “It validates the efforts put in to manage risks, improve security posture and meet requirements within the CareCentrium Environment residing at the Flexential datacenter in Tampa.”
About Chapters Health System As a progressive leader and premier healthcare organization, Chapters Health System is dedicated to delivering innovative care throughout chronic illness progression and beyond. Since 1983 as a community-based, not-for-profit organization, Chapters Health has provided choices, education and guidance through its managed affiliates. All offerings are provided to improve the patient/family experience well in advance of end-of-life needs. In 2023, Chapters Health was named a Top Workplaces USA award-winner; in 2022, earned certified status for information security from HITRUST and for the sixth consecutive year was recognized as a great workplace in the Aging Services category by the independent analysts at the Great Place to Work® Institute. To learn more, visit http://www.chaptershealth.org, like us on Facebook or follow us on X and LinkedIn.
FreeOx Biotech lead asset recommended by NIH/NINDS SPAN network for further development. FreeOx Biotech Adds Leadership for Advancing Ox-01 to Phase III and Commercialization
BARCELONA, Spain, Nov. 16, 2023 /PRNewswire-PRWeb/ — FreeOx Biotech SL, a late-stage clinical biopharmaceutical company pioneering the development of a novel drug class for Acute Ischemic Stroke (AIS), announced today that the National Institutes of Health, NINDS’ SPAN (Stroke Preclinical Assessment Network), endorsed Uric Acid (the active ingredient of Ox-01, the company’s Phase III-ready investigational drug) as the only one of five interventional drug candidates for which data supported further clinical evaluation. As reported in SCIENCE TRANSLATIONAL MEDICINE, FreeOx’s lead asset – was shown to be an effective emergency adjunct therapy to Mechanical Thrombectomy (MT) for the treatment of AIS, demonstrating unprecedented efficacy compared to five other candidate interventions. As such, the NINDS also indicated potential interest in funding Ox-01’s Phase III trial. The company has strong intellectual property covering Uric Acid and its use in stroke treatment.
“The NINDS’ endorsement underscores their confidence in the efficacy and potential of Ox-01 as a ground-breaking therapy for acute ischemic stroke. On top of our compelling Phase II data, the Phase III trial, once successfully completed, will pave the way for the marketing authorization of Ox-01 in the U.S. and EU, as an adjunct therapy to mechanical thrombectomy. We are confident that once approved, Ox-01 will significantly reduce disability in AIS patients,” noted Emmett-Phil Coriat, FreeOx Chairman and Chief Executive Officer.
FreeOx also announced today the addition of key personnel to the company’s leadership and advisory teams, including a new Chairman of the Board and Chief Executive Officer; a newly appointed Board Director; and a Strategic Development Advisory Board to lead the company through its upcoming pivotal Phase III clinical program and subsequent commercial registration and marketing activities. Carlos Lurigados, FreeOx’s co-founder and former CEO, has assumed both the Chief Operating and Chief Financial Officer roles.
New Chairman of the Board and Chief Executive Officer: Emmett-Phil Coriat
“FreeOx is uniquely positioned to lead the field of cerebroprotective therapies. Its lead asset has been observed to reperfuse brain vasculature during a stroke as well as to protect the penumbra. The company’s founders pioneered the strategy of administering Uric Acid to restore microcirculation to oxygen-deprived brain cells and were recently recognized by the U.S. National Institutes of Health SPAN program for their breakthrough work. I believe FreeOx will be the first commercial adjunct therapy to address the significant unmet needs and raise the standard of care in stroke. As both Chairman of the Board and CEO, I look forward to the opportunity to collaborate with the company’s leadership and advisors to advance this work first in stroke and later, to even broader neurological indications,” said Emmett-Phil Coriat, newly appointed FreeOx Board Chair and CEO.
Emmett brings to FreeOx more than 25 years of experience in biotech/medtech as a venture capitalist, founder, and CEO of startups, with a successful track record in dealmaking and exits. He has held diverse roles and advisory positions in Canada, the U.S., Israel, and the U.K. As a partner, he led the creation of the Biotech/Medtech transactional advisory practice and co-founded the Boston office for AEC Partners, a strategy and transactional advisory boutique in life sciences. Emmett was previously a partner at T2C2 Capital, a VC fund behind companies such as Enobia Pharma. His accomplishments include successfully innovating with endogenous products, including an asset sale to Eli Lilly in 2015. Emmett holds an MBA from the London Business School (UK), a Pharmacy degree from University of Montreal and a diploma in Intellectual Property Management from McGill University. Emmett is also certified as a Forest Therapy guide, and co-founded PaRx Canada, which has grown to become one of the world’s largest physician-prescribed ecotherapy programs. He began his career at L’Oréal and holds dual Canadian-Spanish citizenship.
New Board Member: Laurent van Lerberghe
Laurent van Lerberghe brings to the FreeOx Board of Directors a wealth of experience, spanning over 25 years in operational and strategic leadership across pharma businesses. He has a strong track record of leading and developing businesses globally. Over the last three years, he served as Chief Strategy Officer at Sanofi, working closely with the CEO and contributing significantly to the company’s growth as one of the architects of multiple strategic acquisitions. He also expedited funding in oncology, genomic medicines, and digital health. Before Sanofi, Laurent held various high-level commercial positions at Abbott for a decade in the US, Europe, and Asia. Laurent’s strategic insights and track record bringing science to patients will play an important role as we continue to develop and partner Ox-01. Laurent is now an entrepreneur investor, focusing on accelerating digital health across Europe, with neurology being one key area.
“FreeOx is well positioned for success, not only in Phase III but also in the field of cerebroprotective therapy where there has been almost no innovation since the approval of Mechanical Thrombectomy. Despite the fact that MT has improved outcomes for stroke patients, there are a significant number of stroke survivors left unable to live independently post-stroke. As such, they ravage healthcare resources, not to mention present often insurmountable challenges to patients and families alike. It is this gap that I believe FreeOx will address with an emergency adjunct AIS treatment that restores brain microcirculation, and thereby raises standard of care worldwide,” added van Lerberghe.
New Development & Strategic Advisory Board (DSAB)
Coriat said that FreeOx has created a new Development and Strategic Advisory Board to support management’s planning for its pivotal trial, Ox-01’s registration, commercialization and market access. He also expects the DSAB to assist in identifying future pipeline opportunities based on FreeOx’s proprietary liposomal formulation platform, including UA and other neurology indications. Appointed to Chair the DSAB is Joan Bigorra, MD, former General Manager of Novartis Pharma Spain. Dr. Bigorra sat on Novartis Pharma’s International Innovation Board and set up programs focused on Market Access Strategy and Structure. Prior to Novartis. he was Medical Director, and Head of R&D for Bayer Healthcare and Boehringer Ingelheim. Angel Chamorro, M.D, FreeOx co-founder and senior scientific advisor will co-chair the DSAB while Tudor G. Jovin, the company’s co-founder and senior medical advisor has agreed to be its first independent member. Tudor is an esteemed expert specializing in both interventional and non-interventional treatments for stroke and cerebrovascular disorders, with over 300 influential publications.
For more information about FreeOx Biotech and its groundbreaking stroke treatment technology, please visit the company’s website at https://freeoxbiotech.com/.
About FreeOx Biotech
FreeOx Biotech is a leading late-stage clinical-stage biopharmaceutical company dedicated to developing Cerebrovascular Protective Therapy, a new drug class for the emergency treatment of Acute Ischemic Stroke (AIS) patients. By focusing on restoring microcirculation homeostasis and enhancing penumbra reperfusion, FreeOx Biotech aims to revolutionize stroke care and improve patient outcomes. FreeOx’ s lead product, Ox-01, is Phase III- ready. FreeOx is building a pipeline based on a proprietary liposomal formulation technology that broadly expands opportunities in neurology. Founded by Dr. Ángel Chamorro, a leading stroke neurologist and pioneer in the use of Uric Acid as an emergency treatment for AIS, FreeOx ‘s novel adjunct drug has been shown to reperfuse the brain microcirculation. By contrast, current emergency AIS treatments are effective only in addressing recanalization (macrocirculation restoration).
ReferralMD’s new Consult Management features and expanded partnership with ConferMED strengthen eConsults, enhancing patient care and cost savings.
MT. PLEASANT, S.C., Nov. 16, 2023 /PRNewswire-PRWeb/ — ReferralMD, the leader in care coordination and patient access technology, announces the release of its new Consult Management features and the extension of its partnership with ConferMED. With eConsults, ReferralMD improves the patient experience, reduces costs, and expands the scope of primary care by providing crucial clinical guidance from specialists.
Primary care providers can confer with specialists through eConsults before making referrals for face-to-face care. Organizations can send consult requests to specialists in their internal network and in the ConferMED virtual network, ensuring that eConsults are reviewed promptly.
The key enhancements in the Consult Management solution include:
Structured Workflow with Customization
Automated Alerts Similar to Referrals
Access to ConferMED Virtual Specialist Network
Customizing In-Network Specialist Availability
Converting Consults to Referrals
New Consult Management Reports
“By extending the care coordination capabilities in our platform, providers can seamlessly incorporate eConsults and Referrals into their workflow through a tight integration with their EHRs,” stated Rick Hammer, Chief Product Officer at ReferralMD. “We are also deepening our collaboration with ConferMED to give our customers access to ConferMED’s impressive network of specialists focused on eConsults.”
Daren Anderson, MD, President of ConferMED, states, “Referrals from primary care to specialists are a pain point for practices and patients. Our partnership with ReferralMD offers a complete end-to-end solution to help primary care providers meet as many of their patient’s needs as possible in their clinics while efficiently managing the process of referring to outside specialists whenever needed.”
With these new Consult Management features, ReferralMD continues to demonstrate its commitment to advancing healthcare technology and providing innovative solutions that revolutionize how primary and specialty care providers collaborate.
About ReferralMD
ReferralMD delivers proven consult and referral management, patient access, and CRM marketing solutions that empower hospitals, health systems, networks, and payers to streamline the referral process, decrease patient leakage, and improve communication between providers and patients. With powerful clinical decision support tools and real-time analytics, ReferralMD helps healthcare providers increase revenue, drive operational efficiencies, and improve customer service. To learn more about ReferralMD, please visit https://getreferralmd.com.
About ConferMED
ConferMED allows primary care providers to quickly and easily communicate with a national network of specialists in all major adult and pediatric medical and behavioral health disciplines via a secure, HIPAA-compliant platform. Questions requiring a specialty consult frequently can be resolved for the PCP without requiring the patient to incur the cost and inconvenience of a specialist visit. ConferMED is currently providing eConsults to primary care providers and practices in 30 states. To learn more, visit http://www.ConferMED.com.
The West Virginia University Health System is West Virginia’s largest health system with more than 3,000 licensed beds and 4,000 providers. Its J.W. Ruby Memorial Hospital was recently named the top hospital in the state by U.S. News & World Report.
“We’re excited to expand our relationship with Highmark to include HHOWV as it works to bring a new Medicaid offering to West Virginia,” said Albert L. Wright, Jr., president and CEO of the WVU Health System. “Through our collaboration, we will work together to improve the health trajectory of the citizens of the state and assist Medicaid and CHIP-eligible individuals to maintain their health and well-being.”
Highmark is a leading health insurer in the state of West Virginia and has in-network contracts with WVU Health System and its affiliated physicians for Highmark’s commercially insured, employer-sponsored health plans, as well as other government programs like Affordable Care Act (ACA) and Medicare Advantage.
People interested in learning more about HHOWV and its work in becoming a Medicaid plan in West Virginia can contact [email protected].
“At Soter Technologies, we are committed to improving the indoor environments where people live, work and learn as well as providing technology to enhance the health and well-being of students. The new design for FlySense™ uses the latest in IoT technology including advanced sensors and solid-state hardware, which has allowed Soter Technologies to reduce the cost of our technology and make it more affordable for schools to deploy multiple units,” said Derek Peterson, Founder and Chief Executive Officer of Soter Technologies.
Soter Technologies has included with the release of the FlySense™ FS300 and software that powers it, encrypted blockchain security technology. This technology was implemented to give school administrators peace of mind knowing that Soter’s IoT environmental sensors are safe and secure from hackers who seek to access school districts networks or computer systems.
“Using technology to deter and reduce vaping and bullying on school campuses is only part of the Soter Technologies solution. We want to see students break their unhealthy vaping habits or nicotine addiction and engage in positive interactions with their peers. We have found that when schools use our technology as a tool to enhance health and wellness and combine them with health and safety awareness programs, they see a significant decrease in vaping on their campuses,” said Peterson.
Ronkonkoma, New York-based Soter Technologies is committed to creating advanced technology to protect the health and wellbeing of students and the public around the world. Technology is deployed in schools, commercial facilities and public spaces. Soter is the first in the world to introduce a vape and bullying detection and alert system for schools – FlySense®‥Vaping & Elevated Sound Detector. The Soter name is inspired by Greek mythology wherein Soter is the personification of safety, deliverance, and preservation from harm. For more information about the company, its services, and products visit:‥http://www.sotertechnologies.com.
Baldwin Brothers has been serving local communities since 1980, offering compassionate and personalized funeral and cremation services. With their expansion into Tarpon Springs, they aim to provide the same level of care and dedication to families in the area, including nearby communities such as New Port Richey, Palm Harbor, Lutz, and Dunedin.
TARPON SPRINGS, Fla., Nov. 16, 2023 /PRNewswire-PRWeb/ — Baldwin Brothers Funeral & Cremation Society of Florida proudly announces the opening of their new location in Tarpon Springs. The facility, which began operations in October, is located at 39346 US Hwy 19 N, Tarpon Springs, FL 34689.
Baldwin Brothers has been serving local communities since 1980, offering compassionate and personalized funeral and cremation services. With their expansion into Tarpon Springs, they aim to provide the same level of care and dedication to families in the area, including nearby communities such as New Port Richey, Palm Harbor, Lutz, and Dunedin.
The new location offers a range of services, including:
Pre-planning for funerals and cremations, allowing individuals and families to make arrangements in advance and alleviate the stress of decision-making during difficult times.
Funeral and memorial planning, with experienced directors to guide families in creating meaningful celebrations of life.
Cremation services, offering various options for urns, scattering, and burial.
Special services for veterans.
Baldwin Brothers take pride in their commitment to going above and beyond for the families they serve. Their Tarpon Springs location is equipped with modern amenities and a dedicated staff ready to assist with all funeral and cremation needs.
For more information or to make arrangements, contact Baldwin Brothers Funeral & Cremation Society at (727)-290-2015 or via email at [email protected].
About Brothers Funeral & Cremation Society of Florida: Baldwin Brothers has been a trusted name in funeral and cremation services in Florida since 1980. With a focus on transparency, affordability, and personalized care, they have become a preferred choice for many families across the state.
In addition to his government service, Dr. Shulkin is a renowned healthcare executive who has held leadership positions at several prominent hospitals and health systems. Notably, he served as the Chief Executive Officer of Beth Israel in New York and Morristown Medical Center in New Jersey, where he drove strategic initiatives and improved patient outcomes.
“Dr. Shulkin’s deep understanding of healthcare systems, both in government and the private sector, is invaluable,” commented Philipp von Gilsa, CEO of Kontakt.io. “With his guidance, we will continue to trailblaze in our relentless effort to digitally transform health systems and help them optimize operations and transform experiences.”
“I follow health technology closely, and I have found Kontakt.io’s solutions highly differentiated and compelling,” stated Dr. Shulkin. “Providers today are prioritizing improved efficiencies and workforce issues. Kontakt.io offers best-in-class solutions for these priorities.”
For more information about Kontakt.io’s healthcare solutions, please visit kontakt.io/solutions-healthcare.
About Kontakt.io
Kontakt.io is the leader in Inpatient Journey Analytics. By understanding how patients and equipment move through the care delivery process, we uncover waste, optimize workflows, streamline capacity, and help your staff and patients feel seen and valued. Using AI, IoT, and RTLS, we enable responsive health systems that anticipate and adapt to constantly changing operational and human needs. Since 2013, Kontakt.io has provided solutions to +32,000 end users, delivered via +1,200 partners, and deployed +4 million IoT devices in the field.
